The risks include, but are not limited to: Development of primary pulmonary hypertension [see Warnings and Precautions (5.2)] Development of serious valvular heart disease [see Warnings and Precautions (5.3)] Effects on the ability to engage in potentially hazardous tasks [see Warnings and Precautions (5.5)] The risk of an increase in blood pressure [see Warnings and Precautions (5.8) and Adverse Reactions (6)] The risk of interactions [see Contraindications (4), Warnings and Precautions (5) and Drug Interactions (7)] See also, for example, Adverse Reactions (6) and Use in Specific Populations (8)
Environmental Conditions: Store unopened vials at controlled room temperature (typically 2025 C) as directed
Well, there are quite a few reasons you might be feeling hungry when taking a semaglutide medication
Tirzepatide (Mounjaro, Zepbound) Tirzepatide is a dual agonist at GLP-1 and GIP receptors
Many anecdotal protocols range between 2001000 mcg per day, but individual needs differ
Half-life ~30 min plasma half-life reported in rat models (subcutaneous administration)
